Biodefense Market

The biodefense market is estimated in terms of market size to be USD 0.89 billion in 2025 to USD 1.81 billion by 2030 at a CAGR of 15.1% during the forecast period. The biodefense market is driven by rising global threats of bioterrorism, increasing frequency of emerging infectious diseases, and growing investments by governments in national security and pandemic preparedness. Some of the key players in the biodefense market include STERIS (US), ASP International GmbH (a subsidiary of Fortive) (US), Ushio  Inc. (Japan), Sotera Health Company (US), and Bioquell, An Ecolab Solution (UK). These players have incorporated various organic and inorganic growth strategies, including collaborations, acquisitions, product launches, partnerships, agreements, and expansions, to strengthen their international footprint and capture a greater share of the biodefense market. These strategies have allowed the market players to expand across geographies by offering various Biodefense solutions.

In February 2025, Thermo Fisher Scientific (US) announced the acquisition of the Solventum (US) Purification and Filtration business for USD 1.5 billion in cash. This strategic acquisition will expand Thermo Fisher’s bioproduction capabilities, particularly in filtration technologies essential for biologics manufacturing. The deal strengthens Thermo Fisher’s position in the high-growth biopharmaceutical market by integrating Solventum’s advanced membrane and purification technologies into its existing bioprocessing portfolio.

To know about the assumptions considered for the study download the pdf brochure

Major Biodefense Companies Include:

• STERIS (US)
• ASP International GmbH (a subsidiary of Fortive) (US)
• Ushio  Inc. (Japan)
• Sotera Health Company (US)
• Bioquell, An Ecolab Solution (UK)

In June 2020, Ushio Inc.(Japan) announced a strategic alliance to supply Acuity Brands, Inc.(US) with its Care222 ultraviolet disinfection module, a far-UVC (222nm) technology that inactivates viruses and bacteria without harming human skin or eyes. Through this partnership, Acuity Brands will integrate the Care222 modules into its lighting fixtures for use in occupied indoor spaces such as hospitals, offices, and schools. The deal enhances both companies’ positions in the growing market for safe, continuous UV-based disinfection solutions aimed at improving public health and indoor air safety.

STERIS is a leading global provider of infection prevention, decontamination, and surgical solutions, dedicated to improving patient care and safety across healthcare, pharmaceutical, and research environments. STERIS offers an extensive product and service portfolio, including sterilizers, surgical tables and lights, endoscopy equipment, decontamination systems, and instrument processing consumables. It also provides outsourced sterilization and laboratory services. In the field of biodefense, STERIS contributes through its advanced vaporized hydrogen peroxide (VHP) and steam sterilization technologies, high-level disinfection systems, and contamination control solutions used in biosafety laboratories, military facilities, and emergency preparedness units. These solutions are critical for neutralizing biological threats, supporting bio-containment protocols, and ensuring infection control during public health emergencies and bioterrorism response efforts. The company maintains a wide global presence with manufacturing, service, and sales operations across North America, Europe, Asia, and Latin America, serving hospitals, pharmaceutical manufacturers, laboratories, and government agencies.

Ushio Inc. is a global provider of light-based technologies and solutions. The company specializes in the development and manufacturing of a wide range of industrial light sources and optical systems for use in electronics, semiconductors, life sciences, and visual imaging. Ushio's product portfolio includes ultraviolet (UV), visible, and infrared light sources, as well as projection and imaging systems, environmental disinfection units, and industrial light modules. In the field of biodefense and public health, Ushio has pioneered the use of 222nm far-UVC light technology, particularly through its Care222® filtered excimer lamp module, which has been scientifically validated for inactivating airborne pathogens, including SARS-CoV-2 without harming human skin or eyes. This UV-C innovation is being adopted in hospitals, public transportation, and other high-risk indoor environments, supporting biosafety and infection control through safe, continuous air and surface disinfection.

Market Ranking

The biodefense market is highly competitive, with five main players collectively holding 15-20% of the total market share. STERIS (US) stands out in the biodefense industry, leveraging advanced biodefense technologies. ASP International GmbH (a subsidiary of Fortive) (US) follows with a competitive share, maintaining a strong position in the market and providing biodefense technologies globally. Ushio  Inc. (Japan) accounts for a significant share of the market. Sotera Health Company (US) and Bioquell, An Ecolab Solution (UK), have solidified their performance by offering significant biodefense technologies to the market. The remaining 80-85% of the market is shared among other regional and emerging vendors, contributing to extensive fragmentation and offering opportunities for smaller players to establish a footprint. Market competition is driven by the rising threat of bioterrorism and increasing technological advancements.

Related Reports:

Biodefense Market by Technology (GHz-band Wave, Microwave Heating, RF-EMR, Cold Plasma, Gamma, UV), Product (Decontamination (Sterilization Devices, Disinfection Units), Biosensors, AI Surveillance), Application, Region - Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com